DNA Biomed Solns (TA:DNA) — Stock Price
DNA Biomed Solns (TA:DNA) is currently trading at ILA101.90 ILA, up 0.59% today. Over the past 52 weeks, shares have ranged between ILA86.00 and ILA147.50. This page tracks DNA Biomed Solns's live share price on the TA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see DNA market cap overview.
DNA Biomed Solns (DNA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks DNA Biomed Solns's daily closing share price and trading volume on the TA exchange over the past year, giving a clear view of recent price momentum and liquidity.
DNA Biomed Solns Income Statement — Revenue, Profit & Earnings by Year
DNA Biomed Solns's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ILA306.00K | ILA306.00K | ILA560.00K | ILA0.00 | ILA0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | — | — | — | — | — |
| SG&A | ILA885.00K | ILA1.09 Million | ILA1.23 Million | ILA2.37 Million | ILA1.59 Million |
| Total Operating Expenses | ILA1.82 Million | ILA2.48 Million | ILA6.26 Million | ILA2.37 Million | ILA1.59 Million |
| Operating Income | ILA-1.51 Million | ILA-2.17 Million | ILA-5.70 Million | ILA-2.37 Million | ILA-1.59 Million |
| EBITDA | — | — | — | ILA18.42 Million | ILA-19.26 Million |
| EBIT | — | — | ILA-5.70 Million | ILA-2.37 Million | ILA-1.59 Million |
| Interest Expense | — | — | — | ILA43.00K | ILA3.00K |
| Income Before Tax | ILA23.40 Million | ILA-1.18 Million | ILA-23.54 Million | ILA18.37 Million | ILA-19.27 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | ILA22.10 Million | ILA-1.18 Million | ILA-23.54 Million | ILA18.37 Million | ILA-19.27 Million |
DNA Biomed Solns Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes DNA Biomed Solns's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ILA104.28 Million | ILA80.66 Million | ILA81.99 Million | ILA54.62 Million | ILA18.49 Million |
| Total Current Assets | ILA68.43 Million | ILA66.94 Million | ILA65.93 Million | ILA23.91 Million | ILA80.00K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | — | — | — | — | ILA2.00K |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ILA2.81 Million | ILA1.47 Million | ILA1.88 Million | ILA287.00K | ILA10.54 Million |
| Total Current Liabilities | ILA1.13 Million | ILA685.00K | ILA789.00K | ILA287.00K | ILA10.54 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | ILA241.00K |
| Total Stockholder Equity | ILA101.47 Million | ILA79.19 Million | ILA80.11 Million | ILA54.33 Million | ILA7.95 Million |
| Retained Earnings | ILA-51.44 Million | ILA-73.54 Million | ILA-72.36 Million | ILA-48.82 Million | ILA-67.20 Million |
DNA Biomed Solns Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how DNA Biomed Solns generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ILA1.61 Million | ILA-678.00K | ILA-354.00K | ILA-2.33 Million | ILA-611.00K |
| Capital Expenditures | ILA0.00 | ILA0.00 | ILA0.00 | ILA0.00 | ILA0.00 |
| Free Cash Flow | ILA1.61 Million | ILA-678.00K | ILA-354.00K | ILA-2.33 Million | ILA-611.00K |
| Investing Cash Flow | — | — | ILA854.00K | ILA-1.43 Million | ILA-1.43 Million |
| Financing Cash Flow | — | — | ILA41.05 Million | ILA27.40 Million | ILA280.00K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ILA172.00K | ILA67.00K | ILA3.42 Million | ILA973.00K | ILA445.00K |
| Depreciation | — | — | — | — | ILA99.00K |
| Change in Cash | ILA1.61 Million | ILA618.00K | ILA42.04 Million | ILA23.65 Million | ILA-331.00K |
DNA Biomed Solns Earnings History — EPS Actual vs. Analyst Estimates
Track DNA Biomed Solns's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for DNA Biomed Solns.